rV-NY-ESO-1/rF-NY-ESO-1 prime-boost breast cancer vaccine (Ludwig Institute/Therion)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamerV-NY-ESO-1/rF-NY-ESO-1 prime-boost breast cancer vaccine (Ludwig Institute/Therion)
Drug Alias NameNY-ESO-1 pox-virus cancer vaccine (Therion/Ludwig Institute)rV-NYESO-1/rF-NYESO-1 vaccine (Therion/Ludwig Institute for Cancer Research)
ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionCancer/testis antigen 1 modulators
TargetsCancer/testis antigen 1
Therapy Area/IndicationsBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesWestern Europe
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofi Pasteur SaTherion Biologics CorpLudwig Institute For Cancer Research
Active IndicationsN/A
Inactive IndicationsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A